Epizyme (Nasdaq:EPZM) - Prezzo delle azioni, notizie e analisi

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

EPZM Panoramica delle azioni

Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. Maggiori dettagli

EPZM analisi fondamentale
Punteggio fiocco di neve
Valutazione	3/6
Crescita futura	2/6
Prestazioni passate	0/6
Salute finanziaria	0/6
Dividendi	0/6

Premi

Si prevede che i ricavi cresceranno 37.59% all'anno

Analisi del rischio

Prezzo delle azioni altamente volatile negli ultimi 3 mesi

Patrimonio netto negativo

Gli azionisti sono stati sostanzialmente diluiti nell'ultimo anno

Ha meno di 1 anno di pista di cassa

+ 1 più rischio

Epizyme, Inc. Concorrenti

Eagle Pharmaceuticals

OTCPK:EGRX

US$10.8m

Sutro Biopharma

NasdaqGM:STRO

US$215.2m

Karyopharm Therapeutics

NasdaqGS:KPTI

US$105.3m

Sangamo Therapeutics

NasdaqCM:SGMO

US$404.8m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Epizyme
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$1.47
Massimo di 52 settimane	US$5.80
Minimo di 52 settimane	US$0.41
Beta	-0.42
1Variazione di 1 mese	-0.68%
Variazione a 3 mesi	182.37%
Variazione di 1 anno	-72.78%
3Variazione a 3 anni	-89.29%
Variazione a 5 anni	-89.54%
Variazione dall'IPO	-93.61%

Notizie e aggiornamenti recenti

Epizyme GAAP EPS of -$0.21, revenue of $27.5M

Aug 09

Epizyme Acquisition By Ipsen: CVR Value

Jul 05

Recent updates

Epizyme GAAP EPS of -$0.21, revenue of $27.5M

Aug 09

Epizyme Acquisition By Ipsen: CVR Value

Jul 05

Some Epizyme, Inc. (NASDAQ:EPZM) Analysts Just Made A Major Cut To Next Year's Estimates

May 16

Epizyme: Taking Advantage Of Recent Sell-Off

Nov 25

Health Check: How Prudently Does Epizyme (NASDAQ:EPZM) Use Debt?

Sep 14

Industry Analysts Just Made A Sizeable Upgrade To Their Epizyme, Inc. (NASDAQ:EPZM) Revenue Forecasts

Aug 10

Epizyme, Inc. (NASDAQ:EPZM) Analysts Just Trimmed Their Revenue Forecasts By 41%

Feb 25

Is Epizyme (NASDAQ:EPZM) Using Too Much Debt?

Jan 16

Epizyme says Boehringer terminates collaboration agreement

Dec 24

Would Shareholders Who Purchased Epizyme's (NASDAQ:EPZM) Stock Year Be Happy With The Share price Today?

Dec 12

Epizyme Q3 2020 Earnings Preview

Nov 05

Rendimenti per gli azionisti

	EPZM	US Biotechs	US Mercato
7D	-3.3%	4.0%	2.0%
1Y	-72.8%	18.0%	32.4%

Ritorno vs Industria: EPZM ha avuto una performance inferiore rispetto al US Biotechs che ha registrato un rendimento 18 % nell'ultimo anno.

Rendimento vs Mercato: EPZM ha avuto una performance inferiore al mercato US che ha registrato un rendimento 32.4 % nell'ultimo anno.

Volatilità dei prezzi

Is EPZM's price volatile compared to industry and market?
EPZM volatility
EPZM Average Weekly Movement	19.9%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.9%
10% least volatile stocks in US Market	3.1%

Prezzo delle azioni stabile: Il prezzo delle azioni di EPZM è stato volatile negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 20% ) di EPZM è rimasta stabile nell'ultimo anno, ma è comunque superiore al 75% delle azioni US.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2007	250	Grant Bogle	www.epizyme.com

Epizyme, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Epizyme con la sua capitalizzazione di mercato?
EPZM statistiche fondamentali
Capitalizzazione di mercato	US$247.50m
Guadagni(TTM)	-US$207.73m
Ricavi(TTM)	US$53.01m

4.7x

Rapporto P/S

-1.2x

Rapporto P/E

EPZM è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
EPZM Conto economico (TTM)
Ricavi	US$53.01m
Costo del fatturato	US$10.79m
Profitto lordo	US$42.22m
Altre spese	US$249.95m
Guadagni	-US$207.73m

Ultimi guadagni dichiarati

Jun 30, 2022

Prossima data di guadagno

n/a

Utile per azione (EPS)	-1.23
Margine lordo	79.64%
Margine di profitto netto	-391.88%
Rapporto debito/patrimonio netto	-1,148.4%

Come si è comportato EPZM nel lungo periodo?

Vedi performance storica e confronto

This company listing is no longer active

EPZM Panoramica delle azioni

Premi

Analisi del rischio

Epizyme, Inc. Concorrenti

OTCPK:EGRX

US$10.8m

NasdaqGM:STRO

US$215.2m

NasdaqGS:KPTI

US$105.3m

NasdaqCM:SGMO

US$404.8m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Ipsen Biopharmaceuticals, Inc. completed the acquisition of Epizyme, Inc. (NasdaqGS:EPZM) from RP Management LLC and others.

Epizyme, Inc.(NasdaqGS:EPZM) dropped from S&P Global BMI Index

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Epizyme GAAP EPS of -$0.21, revenue of $27.5M

Epizyme Acquisition By Ipsen: CVR Value

Ipsen Biopharmaceuticals, Inc. entered into a definitive merger agreement to acquire Epizyme, Inc. (NasdaqGS:EPZM) from RP Management LLC and others for approximately $250 million.

Recent updates

Ipsen Biopharmaceuticals, Inc. completed the acquisition of Epizyme, Inc. (NasdaqGS:EPZM) from RP Management LLC and others.

Epizyme, Inc.(NasdaqGS:EPZM) dropped from S&P Global BMI Index

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Epizyme GAAP EPS of -$0.21, revenue of $27.5M

Epizyme Acquisition By Ipsen: CVR Value

Ipsen Biopharmaceuticals, Inc. entered into a definitive merger agreement to acquire Epizyme, Inc. (NasdaqGS:EPZM) from RP Management LLC and others for approximately $250 million.

Epizyme Presents Updates from SYMPHONY-1 Tazemetostat + R² Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2022 ASCO Annual Meeting

Epizyme Receives Non-Compliance Letter from Nasdaq

Epizyme Receives Non-Compliance Letter from Nasdaq

Consensus revenue estimates fall by 12%

Some Epizyme, Inc. (NASDAQ:EPZM) Analysts Just Made A Major Cut To Next Year's Estimates

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$6.60

Shefali Agarwal Resigns from Epizyme, Inc., Effective April 6, 2022

Epizyme, Inc., Annual General Meeting, May 17, 2022

Consensus forecasts updated

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Epizyme, Inc. has completed a Follow-on Equity Offering in the amount of $85.000001 million.

Price target decreased to US$9.02

Price target decreased to US$9.20

Epizyme, Inc. Provides Revenue Guidance for the Fourth Quarter and Year Ended December 31, 2021

Price target increased to US$12.25

Consensus revenue estimates increase by 19%

Epizyme, Inc. Presents Updates from SYMPHONY-1 Tazemetostat + R² Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2021 ASH Annual Meeting

Epizyme, Inc. Presents Preclinical Data and Phase 1/1b Trial Design on the Company’s SETD2 Inhibitor, EZM0414, at the 2021 ASH Annual Meeting

Epizyme, Inc. to Present New Data from Oncology Portfolio at 2021 American Society of Hematology Annual Meeting

Epizyme: Taking Advantage Of Recent Sell-Off

Third quarter 2021 earnings released: US$0.64 loss per share (vs US$0.55 loss in 3Q 2020)

Health Check: How Prudently Does Epizyme (NASDAQ:EPZM) Use Debt?

Director Kevin Conroy has joined 4th company board

Consensus revenue estimates increase to US$53.4m

Second quarter 2021 earnings released: US$0.63 loss per share (vs US$0.58 loss in 2Q 2020)

Price target decreased to US$11.14

Industry Analysts Just Made A Sizeable Upgrade To Their Epizyme, Inc. (NASDAQ:EPZM) Revenue Forecasts

Epizyme, Inc.(NasdaqGS:EPZM) dropped from Russell 3000E Value Index

Epizyme: Potential Comeback With Tazemetostat After Initial Sales Challenge

Is Epizyme (NASDAQ:EPZM) Using Too Much Debt?

Epizyme gains as peer Constellation attracts sizable premium from MorphoSys

Epizyme, Inc. 2021 Q1 - Results - Earnings Call Presentation

First quarter 2021 earnings released: US$0.69 loss per share (vs US$0.51 loss in 1Q 2020)

Independent Chairman recently bought US$500k worth of stock

Epizyme, Inc. Outlines Clinical Progress, Tazverik Development Strategy and Pipeline Priorities During Company’s Strategic Vision Call

Analysts lower revenue estimates to US$49.1m

Epizyme, Inc. (NASDAQ:EPZM) Analysts Just Trimmed Their Revenue Forecasts By 41%

Full year 2020 earnings released: US$2.30 loss per share (vs US$1.93 loss in FY 2019)

Price target lowered to US$21.25

Revenue and earnings beat expectations

Epizyme, Inc. Provides Update on Clinical Trials

New 90-day low: US$10.67

Is Epizyme (NASDAQ:EPZM) Using Too Much Debt?

Epizyme says Boehringer terminates collaboration agreement

Would Shareholders Who Purchased Epizyme's (NASDAQ:EPZM) Stock Year Be Happy With The Share price Today?

Independent Director recently bought US$60k worth of stock

Price target lowered to US$23.50

Third quarter 2020 earnings released: US$0.55 loss per share

Revenue and earnings miss expectations

Analysts update estimates

Third quarter 2020 earnings released: US$0.55 loss per share